4 research outputs found
The role of depression in the relationship between cognitive decline and quality of life among breast cancer patients
Parental Depressive Symptoms and Children’s School Attendance and Emergency Department Use: A Nationally Representative Study
The effect of training interventions on physical performance, quality of life, and fatigue in patients receiving breast cancer treatment: a systematic review
Cardiovascular and Central Nervous System Toxicity by Anticancer Drugs in Breast Cancer Patients
Breast cancer is one of the most malignant diseases, associated with high rate mortality. In this chapter a particular attention is paid on cardiovascular and central nervous system toxicity induced by chemotherapeutic agents used for both primary and metastatic treatment of this life-threatening pathology. With respect to traditional drugs, including anthracyclines, taxanes, and fluoropyrimidines, the more recent targeted therapies, such as human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor (VEGF), aimed to ameliorate anticancer activity and to reduce toxic effects by affecting more specific molecular sites. However, despite the improvement in breast cancer treatment, these novel drugs were also found to be associated, even if at a lesser extent, with important side effects, such as cardiotoxicity, with consequent heart failure. For this reason, the cardiovascular and brain safety profile of all anticancer drugs and protocols remains important items to be carefully evaluated in breast cancer patients